肿瘤防治研究2026，Vol.53Issue(1)：1-16,16.DOI:10.3971/j.issn.1000-8578.2026.25.0819
重组人粒细胞集落刺激因子临床应用管理中国专家共识(2026版)
Chinese Expert Consensus on Clinical Application and Management of Recombinant Human Granulocyte-Colony Stimulating Factor(2026 Edition)
中国抗癌协会整合肿瘤药学委员会 1中国抗癌协会肿瘤内科学专业委员会 1董梅 2沈波3
作者信息
- 2. 哈尔滨医科大学附属肿瘤医院||中国抗癌协会整合肿瘤药学委员会
- 3. 江苏省肿瘤医院||中国抗癌协会肿瘤内科学专业委员会
- 折叠
摘要
Abstract
Neutropenia is a common hematologic toxicity during antitumor therapy and can induce treatment delays,dose reduction,and even febrile neutropenia(FN),thereby causing poor prognosis.Human granulocyte-colony stimulating factor(G-CSF)has been widely used in the treatment of neutropenia,enabling early disease prevention,reduction in FN incidence,and improvement in antitumor efficacy.However,the standardization of G-CSF in clinical application still needs to be enhanced,and oncology pharmacists play a crucial role in its standardized application.Together with multiple professional committees,the Chinese Anti-Cancer Association Integrated Oncology Pharmacy Committee has developed the consensus to optimize G-CSF application,reduce medical costs,improve G-CSF pharmaceutical monitoring,and enhance patient benefits.关键词
人粒细胞集落刺激因子/中性粒细胞减少症/恶性肿瘤/临床应用Key words
Human granulocyte-colony stimulating factor/Neutropenia/Malignant tumors/Clinical application分类
医药卫生引用本文复制引用
中国抗癌协会整合肿瘤药学委员会,中国抗癌协会肿瘤内科学专业委员会,董梅,沈波..重组人粒细胞集落刺激因子临床应用管理中国专家共识(2026版)[J].肿瘤防治研究,2026,53(1):1-16,16.
